VeriSIM Life Powers the AI Behind Next-Generation Cell Preservation

VeriSIM Life Powers the AI Behind Next-Generation Cell Preservation




VeriSIM Life Powers the AI Behind Next-Generation Cell Preservation

  • Company brings mechanistic AI to ARPA-H’s up to $6.5 million initiative to transform cell therapy preservation and eliminate cold-chain dependence.

SAN FRANCISCO–(BUSINESS WIRE)–VeriSIM Life, a pioneer in mechanistic artificial intelligence for drug discovery and development, today announced its participation in an initiative funded by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS) program. The initiative aims to revolutionize how living cells are preserved, stored, and transported, addressing one of the most significant barriers to scaling advanced cell therapies.

Led by DesiCorp, the multidisciplinary consortium includes VeriSIM Life, Ossium Health, Via Therapeutics, the University of Louisville, and the University of Texas at Austin. Together, the team will combine expertise in computational biology, cellular engineering, formulation science, and advanced manufacturing to develop technologies that could eliminate the need for ultra-cold storage.

VeriSIM Life will contribute its mechanistic AI expertise to help accelerate the development of next-generation cell preservation technologies. By bringing predictive biological intelligence into the development process, VeriSIM aims to support more efficient innovation and reduce the experimental complexity of preserving living cells while maintaining their viability and function.

“AI’s greatest opportunity in life sciences is not simply discovering new medicines, but fundamentally transforming how we develop and deliver them,” said Dr. Jo Varshney, Founder and CEO of VeriSIM Life. “Through this ARPA-H initiative, we are extending the power of mechanistic AI to one of the most challenging frontiers in biotechnology: preserving living systems outside the human body. Success could reshape the economics, scalability, and global accessibility of cell-based therapies.”

“The ARPA-H BoSS program presents an exciting opportunity to fundamentally change how cell-based medicines are preserved and distributed,” said Dr. Brett Janis, co-founder and CEO of DesiCorp. “Addressing the scientific and engineering challenges associated with room-temperature preservation requires a multidisciplinary approach, and we are excited to collaborate with VeriSIM Life to combine AI-driven modeling with our team’s experimental capabilities. Together, we aim to accelerate the development of innovative preservation technologies that could ultimately make life-saving cell therapies more accessible to patients.”

The initiative represents a significant expansion of VeriSIM Life’s mechanistic AI capabilities beyond drug discovery and development into biostabilization and biomanufacturing, reinforcing the company’s broader vision of building predictive intelligence across the therapeutic lifecycle.

About VeriSIM Life

VeriSIM Life is pioneering mechanistic AI to transform drug discovery and development. Its proprietary BIOiSIM® platform combines mechanistic biosimulation with machine learning to predict biological outcomes, reduce translational risk, and accelerate therapeutic development. Through collaborations with pharmaceutical companies, research institutions, and government agencies, VeriSIM Life is building a more predictive and efficient future for life sciences.

Contacts

Media Contact
Emily Spady

marketing@verisimlife.com

Meta Cell Technology Brings Together International Medical Educators for First MCT Academy – Train the Trainers

Meta Cell Technology Brings Together International Medical Educators for First MCT Academy – Train the Trainers




Meta Cell Technology Brings Together International Medical Educators for First MCT Academy – Train the Trainers

Physicians and scientific experts from MCT’s international network met in Crete for advanced medical education, scientific exchange and the formal recognition of MCT Trainers.


BARCELONA, Spain–(BUSINESS WIRE)–Meta Cell Technology has held the first edition of MCT Academy – Train the Trainers in Hersonissos, Crete, from 2 to 4 October 2026, bringing together experienced physicians, scientific experts and medical educators from its international network.

Under the motto “Learning. Sharing. Leading.”, the programme combined scientific foundations, clinical protocols, evidence review, guest faculty sessions and multidisciplinary discussion. Designed for professionals actively involved in physician education, the initiative marks a further step in strengthening MCT’s educational and scientific network across more than 70 countries.

An Interdisciplinary Approach to Regenerative Medicine

The programme brought together professionals from orthopaedic surgery and traumatology, sports medicine, gynaecology, trichology, dermatology, aesthetic medicine and regenerative medicine. The international faculty included Dr. Edgar Michael T. Eufemio, Dr. Madiha Azmat Rao, Dr. Luciana Macedo and Cristina Domínguez, alongside sessions led by Dr. Hernán Pinto, Chief Scientific Officer and Co-founder of Meta Cell Technology.

The scientific agenda was developed under the supervision of the Scientific Committee, comprising Dr. Laura Cordero, Elena Sánchez Vizcaíno, Sara Cervantes and Adrià Reigosa, ensuring a focus on current evidence, clinical relevance and continuing medical education.

Dr. Hernán Pinto, Chief Scientific Officer and Co-founder of Meta Cell Technology

“Medical education should not be limited to teaching a protocol. Physicians need to understand the scientific rationale, examine the evidence critically and recognise the clinical context in which a technology may be relevant”

International Scientific Exchange and Trainer Certification

The meeting coincided in Crete with Suprema Experience Greece, organised by Suprema MED, MCT’s distribution partner in Brazil. The two programmes created further opportunities for scientific exchange and networking between the international MCT community and Brazilian physicians.

A key milestone was the formal recognition of physicians from different countries as MCT Trainers, who received their certificates at the closing session. The certification marks a new stage in developing MCT’s international trainer network, supporting peer-to-peer scientific education and knowledge exchange across markets.

Philippe Plan, Chief Executive Officer of Meta Cell Technology

“International growth needs to be accompanied by investment in knowledge. As MCT expands into new markets, our responsibility is not only to make the technology available, but also to ensure that physicians and our local partners have access to high-quality scientific education. MCT Academy is becoming an important part of how we approach that growth, by connecting people, knowledge and clinical experience across countries.”

Through MCT Academy, the company continues to develop in-person educational programmes, international webinars and evidence-led scientific content to support healthcare professionals.

ABOUT MCT ACADEMY

MCT Academy is Meta Cell Technology’s scientific and medical education platform, supporting evidence-led education and knowledge exchange around photothermal biomodulation in regenerative medicine.

ABOUT META CELL TECHNOLOGY

Meta Cell Technology is a Barcelona-based medical technology company focused on conditioning autologous biological material through photothermal biomodulation. It operates internationally through distribution partners and healthcare professionals, with a portfolio that includes CE-marked medical devices and an ISO 13485-certified quality management system.

Contacts

Sherry Cacay Llanes
Marketing Manager

globalmarketing@clinipro.net | metacelltech.com

Impulse London to Premiere Chemsex Documentary Chemtrail: The Journey at Rich Mix

Impulse London to Premiere Chemsex Documentary Chemtrail: The Journey at Rich Mix




Impulse London to Premiere Chemsex Documentary Chemtrail: The Journey at Rich Mix

LONDON–(BUSINESS WIRE)–#ChemsexAwareness—Impulse London invites the LGBTQ+ community and allies to screenings of Chemtrail: The Journey on 7th and 8th November at 2pm at Rich Mix. The documentary shares the realities of chemsex in London and the search for support and recovery through the lived experiences of Ben, Pank, Declan, and Matthew. Tickets available at Eventbrite.

Chemsex remains a central focus of Impulse London’s advocacy work. The organisation raises awareness, signposts people to support, and works to keep Londoners, especially queer men, safe. In 2024 and 2025, it staged Chemtrail and Chemtrail: This is Killing Us, to raise awareness and support harm reduction and recovery. This year’s event goes deeper, using lived experience and storytelling to challenge stigma and show that help is available.

WHAT:

Documentary screening: Chemtrail: The Journey

WHEN:

7th and 8th November at 2pm

WHERE:

Rich Mix

35–47 Bethnal Green Road, London E1 6LA

 

Tickets available at Eventbrite

MEDIA CONTACT:

Charlie Reynolds, Marketing Director, Impulse London Charlie.Reynolds@impulsegrp.org

Alex Tridico, president of Impulse London, said, “Over the past two years, our Chemtrail events have used art to continue conversations about chemsex in our community. This film takes that further. By listening to people’s stories in their own words, we can better understand the different routes people took to find support and recovery, and we hope to make it easier for others to take that first step.”

Chemtrail: The Journey was brought to life by LGBTQ+ directors and producers John Reavy and Jordi Estapé Montserrat. Working with Impulse London, the duo have created an emotional film that shares four stories with sensitivity and respect.

Each screening will be followed by a talk exploring themes raised in the documentary, with a focus on support, recovery, and the different experiences and pathways people may take. Tickets are £5 (or pay what you can), and free community tickets are available. All proceeds will go to Controlling Chemsex and London Friend.

Impulse London is a community-led advocacy organisation working with gay and queer men. Through advocacy, events, education and community engagement, Impulse works to create spaces for open conversations around mental health, substance use awareness, sexual health, and social justice. Impulse London is an affinity group of AIDS Healthcare Foundation.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 3.3 million people across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

Contacts

MEDIA CONTACT:

Charlie Reynolds, Marketing Director, Impulse London Charlie.Reynolds@impulsegrp.org

Las Vegas Rallies for City of Hope’s First Walk for Hope in the City, Raising Funds for Lifesaving Cancer Research

Las Vegas Rallies for City of Hope’s First Walk for Hope in the City, Raising Funds for Lifesaving Cancer Research




Las Vegas Rallies for City of Hope’s First Walk for Hope in the City, Raising Funds for Lifesaving Cancer Research

Patients, survivors, caregivers and families joined entertainer Donny Osmond, the event’s “Headliner for Hope,” to honor loved ones and stand with people facing cancer

LAS VEGAS–(BUSINESS WIRE)–#cityofhope–City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, welcomed more than 1,700 patients, survivors, caregivers and supporters to its inaugural Walk for Hope Las Vegas on Saturday, Oct. 24. Together, walkers raised more than $220,000 and counting for lifesaving cancer research and care.




Entertainer and longtime City of Hope supporter Donny Osmond served as the event’s inaugural “Headliner for Hope,” helping introduce Walk for Hope to the Las Vegas community and rally participation in the lead-up to the event. He and his wife, Debbie, led Team Debbie & Donny Osmond, joining walkers at the Civic Center in downtown Las Vegas.

With a nearly 50-year history, Walk for Hope is City of Hope’s signature community fundraising campaign and event series, uniting patients, survivors, caregivers and supporters to honor loved ones, celebrate survivors and raise funds for lifesaving cancer research and compassionate care. In 2023, Walk for Hope expanded beyond Southern California to communities where City of Hope operates cancer centers, and now continues its growth with the inaugural Las Vegas event.

Philanthropy powers City of Hope’s work, from early-stage discovery to the clinical trials that bring new therapies to patients.

Lennar, one of the nation’s leading homebuilders, served as a local sponsor of the event, helping bring the walk to the Las Vegas community.

“Walk for Hope is hope in action, and the Las Vegas community has shown us what that truly means,” said Kristin Bertell, chief philanthropy officer at City of Hope. “City of Hope isn’t defined solely by where we have buildings, but by the people and communities who believe in our mission to end cancer for all. For years, Las Vegas donors, volunteers and corporate partners have helped advance that mission, and this inaugural walk is a powerful reflection of their continued commitment. We’re deeply grateful to Lennar and everyone who came together to make this special day possible.”

The walk brought together a community where access to specialized cancer care remains a challenge. Cancer is the second leading cause of death in Nevada, and the state has about half the number of oncologists relative to its population compared with the national average. City of Hope is committed to expanding access to the latest cancer breakthroughs, and its national network offers more than 700 active clinical trials.

“Every person facing cancer deserves access to the expertise, clinical trials, and innovative therapies that can improve outcomes and quality of life,” said Harlan Levine, M.D., president of health innovation and policy at City of Hope. “For patients and families in Nevada, where the need for specialized cancer care is known, creating that access can make a meaningful difference. Developing new drugs, helping them come to market faster and safely, and making them more accessible for patients closer to home are central to our mission to improve the cancer outcomes in the communities we serve.”

Throughout the day, teams of families, friends and coworkers walked in honor of parents, partners and loved ones. Survivors walked alongside them, cheered on by the people who stood by them through treatment.

“Las Vegas is a city of big dreams, and for families facing cancer, the biggest dream is more time with the people they love,” said Las Vegas Mayor Shelley Berkley. “Improving access to quality health care for Nevadans has been a priority throughout my career, and Las Vegas is proud to support Walk for Hope and the research that brings new hope to our community.”

For the Osmonds, the cause is personal. Cancer has touched their family, including the loss of Debbie’s mother.

“Las Vegas has given Debbie and me so much over the years, and walking alongside this community in support of City of Hope was a meaningful way to give back,” said Donny Osmond. “Cancer has touched so many families, including our own. Seeing neighbors come together to honor loved ones and celebrate survivors was a reminder that Las Vegas always shows up when people need it most.”

Among the day’s meaningful moments was a performance of the national anthem by Las Vegas-based entertainer Jennifer “JayBee” Beasley, a Hodgkin lymphoma survivor who received a stem cell transplant at City of Hope after multiple rounds of treatment and a clinical trial. Cancer-free since September 2014, JayBee joined fellow participants at Walk for Hope, lending her voice to a cause that has profoundly shaped her life.

Las Vegas joins a national series of Walk for Hope events that City of Hope hosts each fall in communities across the country, from Chicago and Atlanta to Arizona and Southern California. Each walk brings neighbors together to honor loved ones, celebrate survivors and advance research that benefits patients nationwide. This year’s season continues Nov. 7 in Arizona and Atlanta and concludes Nov. 8 in Los Angeles and Orange County, with virtual participation open to supporters anywhere.

To make a gift, register to participate or learn more, visit cityofhope.org/walkforhope.

About City of Hope

City of Hope’s mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked among the nation’s top cancer centers by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, Orange County, California, campus, a network of clinical care locations across Southern California and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.

Contacts

City of Hope
Bridget Livengood
blivengood@coh.org

The Ferraro Group
Kenzie Papa
Kenzie@theferrarogroup.com
702-858-3108

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy




KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet chemotherapy (8.4 months)

KEYNOTE-C93 is the first Phase 3 trial of a PD-1 inhibitor to show a statistically significant and clinically meaningful improvement in PFS as monotherapy compared to chemotherapy in these patients

Late-breaking results were selected for an official press briefing and will be presented during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 and published simultaneously in The Lancet

RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 KEYNOTE‑C93 trial, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence after receiving prior adjuvant therapy. Results showed KEYTRUDA as monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) for these patients, reducing the risk of disease progression or death by 43% (HR=0.57; [95% CI, 0.42-0.79]; p=0.0002) compared to platinum doublet chemotherapy. These late-breaking results will be presented today during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 [Presentation #LBA12], were selected for an official ESMO press briefing and were published simultaneously in The Lancet.


After a median follow-up of 36.7 months (range, 28.4-50.0), median PFS was 38.2 months (95% CI, 17.9-NR) for KEYTRUDA versus 8.4 months (95% CI, 6.8-10.4) for chemotherapy, with 36-month PFS rates of 52.8% (95% CI, 44.2-60.7) versus 30.0% (95% CI, 22.4-37.9), respectively. In addition to an improvement in PFS, a favorable trend in overall survival (OS), the trial’s other primary endpoint, was observed for KEYTRUDA monotherapy versus platinum doublet chemotherapy (HR=0.77 [95% CI, 0.52-1.15]; p=0.1000). Median OS was not reached (NR) (95% CI, NR-NR) for KEYTRUDA versus NR (95% CI, 38.9-NR) for chemotherapy, with 36-month OS rates of 70.7% (95% CI, 62.4-77.5) versus 62.0% (95% CI, 53.1-69.8), respectively. The trial is continuing, and follow-up of OS is ongoing. Results will be shared with regulatory authorities worldwide.

“These results highlight the potential of a chemotherapy-free approach for certain patients with dMMR advanced or recurrent endometrial cancer, with pembrolizumab monotherapy demonstrating a clinically meaningful benefit in progression-free survival compared to chemotherapy,” said Dr. Brian Slomovitz, director of Gynecologic Oncology and deputy director of the Braman Comprehensive Cancer Center at Mount Sinai Medical Center in Miami Beach, Florida, and the study’s overall principal investigator. “After years of platinum-based chemotherapy serving as the frontline standard, these findings could help provide an additional treatment option beyond carboplatin plus paclitaxel in combination with KEYTRUDA for these patients.”

“KEYTRUDA is already part of an established treatment regimen with platinum doublet chemotherapy for patients with primary advanced or recurrent endometrial cancer regardless of mismatch repair status, and we’re excited by these results showing its further potential as a monotherapy option for appropriate patients whose tumors are dMMR,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “As incidence rates of endometrial cancer continue to rise, we remain committed to advancing new potential treatment options for women facing this disease.”

Confirmed objective response rate (ORR), a key secondary endpoint, was 64.1% (95% CI, 55.8-71.9) with KEYTRUDA versus 62.1% (95% CI, 53.6-70.0) with chemotherapy; complete response rates were 33.8% and 26.2%, respectively. ORR was not tested for statistical significance at this analysis. Among responders, median duration of response (DOR) was not reached for patients receiving KEYTRUDA versus 10.2 months for patients receiving chemotherapy; the 24-month DOR rate was 77.0% versus 41.3%, and the 36-month DOR rate was 70.7% versus 40.0%, respectively.

The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies, and no new safety signals were identified in either treatment arm. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 18.1% of patients receiving KEYTRUDA (n=149) versus 50.7% of patients receiving chemotherapy (n=144); the most common Grade ≥3 TRAE was anemia, occurring in 2.0% of patients receiving KEYTRUDA compared with 18.1% of patients receiving chemotherapy. Grade ≥3 immune-mediated adverse events and infusion reactions occurred in 7.4% of patients receiving KEYTRUDA and 3.5% of patients receiving chemotherapy.

In the U.S., KEYTRUDA is the only anti-PD-1 therapy with three approved indications for patients with certain types of endometrial cancer. KEYTRUDA is indicated:

  • In combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma;
  • In combination with LENVIMA® (lenvatinib), in collaboration with Eisai, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR), as determined by an FDA-authorized test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation; and
  • As a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Merck has a comprehensive clinical development program evaluating KEYTRUDA (both as monotherapy and in combination with chemotherapy) and sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, in endometrial cancer. As previously announced, TroFuse-005 (ClinicalTrials.gov, NCT06132958), evaluating sac-TMT, met its primary endpoints of PFS and OS, as well as its key secondary endpoint of ORR in patients with endometrial cancer who have previously received platinum-based chemotherapy and immunotherapy. These results are also being presented in a Presidential Symposium at ESMO. In addition, TroFuse-033 (NCT06952504) is enrolling patients with pMMR endometrial cancer to evaluate sac-TMT in an earlier treatment setting of first-line maintenance. The KEYNOTE-B21 trial (NCT04634877) evaluating KEYTRUDA remains ongoing for analysis in the dMMR subgroup.

About KEYNOTE-C93

KEYNOTE-C93 is a randomized, open-label Phase 3 trial (NCT05173987) evaluating KEYTRUDA monotherapy versus carboplatin plus paclitaxel in patients with dMMR advanced or recurrent endometrial cancer who have not previously been treated with prior systemic chemotherapy or who experienced recurrence after receiving prior adjuvant therapy. The trial enrolled 299 patients who were randomized to receive either:

  • KEYTRUDA (400 mg) intravenously every six weeks for up to 18 cycles, or;
  • Combination of paclitaxel (175 mg/m2) and carboplatin (AUC 5 or 6) every three weeks for six cycles.

The trial’s dual primary endpoints are PFS, as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and OS. A key secondary endpoint of the study is ORR.

About endometrial cancer

Endometrial cancer (also referred to as endometrial carcinoma) begins in the inner lining of the uterus, which is known as the endometrium, and is the most common type of cancer in the uterus. More than 90% of uterine body cancers occur in the endometrium. Endometrial cancer is one of the few cancers with increasing mortality. In the U.S., it is estimated there will be approximately 68,270 patients diagnosed with endometrial cancer and approximately 14,450 patient deaths from the disease in 2026. Globally, endometrial cancer is the sixth most common cancer in women and the 15th most common cancer overall.

About Merck’s research in women’s cancers

Merck is advancing research aimed at expanding treatment options for certain breast and gynecologic (ovarian, cervical and endometrial) cancers, with a goal of improving outcomes for more patients affected by these diseases. Breast cancer and gynecologic cancers are the first and second most commonly occurring cancer types among women worldwide, respectively, and Merck aims to provide options to patients facing these devastating diseases. With more than 30 clinical trials in more than 20,000 patients around the world, Merck is driving innovative research to purposefully advance standards of care in women’s cancers. Merck’s research efforts include trials focused on evaluating its medicines in earlier stages, as well as identifying novel mechanisms and new combinations with these treatments. Through our portfolio and pipeline, Merck is working to address the impact of women’s cancers on patients, their families and communities globally.

About KEYTRUDA® (pembrolizumab) injection for intravenous use, 100 mg

KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 2,800 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected Indications in the U.S. for KEYTRUDA® (pembrolizumab)

Endometrial Carcinoma

KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.

KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

See additional selected indications in the U.S. for KEYTRUDA after the Selected Safety Information.

Selected Safety Information for KEYTRUDA

Severe and Fatal Immune-Mediated Adverse Reactions

KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti–PD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.

Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis, 42% interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.

Pneumonitis occurred in 7% (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions. Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of patients. Of the patients who developed pneumonitis, 54% interrupted KEYTRUDA, 63% discontinued KEYTRUDA, and 71% had resolution.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.

Hepatotoxicity and Immune-Mediated Hepatitis

KEYTRUDA as a Single Agent

KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.

KEYTRUDA With Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST) (13%) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT ≥3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT ≥3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT ≥3 ULN subsequently recovered from the event.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77% (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Hypophysitis

KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions. Systemic corticosteroids were required in 94% (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Thyroid Disorders

KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in <0.1% (1) of patients.

Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in <0.1% (2) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8% (237/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.5% (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (17%) receiving KEYTRUDA as a single agent, including Grade 1 (6.2%) and Grade 2 (10.8%) hypothyroidism. The incidence of new or worsening hyperthyroidism was higher in 580 patients with resected NSCLC, occurring in 11% of patients receiving KEYTRUDA as a single agent as adjuvant treatment, including Grade 3 (0.2%) hyperthyroidism. The incidence of new or worsening hypothyroidism was higher in 580 patients with resected NSCLC, occurring in 22% of patients receiving KEYTRUDA as a single agent as adjuvant treatment (KEYNOTE-091), including Grade 3 (0.3%) hypothyroidism.

Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in <0.1% (1) and withholding of KEYTRUDA in <0.1% (1) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Immune-Mediated Nephritis With Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 89% (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9 patients.

Immune-Mediated Dermatologic Adverse Reactions

KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti– PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes.

Contacts

Media Contacts:

Julie Cunningham

julie.cunningham@merck.com

Heather Manhardt

heather.manhardt@merck.com

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

Steven Graziano

(732) 594-1583

Read full story here

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer




Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer

TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy

Results from TroFuse-005 were selected for an official press briefing and will be presented during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 and published simultaneously in The Lancet

Based on these data, the U.S. FDA has accepted for priority review a Biologics License Application for sac-TMT for these patients

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, in patients with advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. At a pre-specified interim analysis, the study demonstrated statistically significant and clinically meaningful improvement in its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as well as its key secondary endpoint of objective response rate (ORR) compared with treatment of physician’s choice (TPC; doxorubicin or paclitaxel). TroFuse-005 is the first global Phase 3 trial and the first ADC to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients with advanced or recurrent endometrial cancer. These late-breaking data will be presented for the first time today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 [Presentation #LBA11], were selected for an official ESMO press briefing, and were published simultaneously in The Lancet.


At the time of analysis, with a median follow-up of 14.0 months, sac-TMT reduced the risk of death by 32% (HR=0.68; 95% CI, 0.55-0.84; P<0.0001), extending median OS by 6.9 months compared with TPC (19.0 months vs. 12.1 months). Sac-TMT also reduced the risk of disease progression or death by 41% (HR=0.59; 95% CI, 0.50-0.70; P<0.0001), extending median PFS by 3.3 months compared with TPC (7.2 months vs. 3.9 months). The study improved ORR by 17.8% (95% CI, 11.6–23.9; P <0.00001), double what was observed in the TPC arm (35.1% vs. 17.3%), and complete responses occurred in 6.1% of patients on the sac-TMT arm and 4.5% of patients on the chemotherapy. Responses were durable, with a median duration of response of 11.1 months (95% CI, 9.2–13.0) in the sac-TMT arm and 6.9 months (95% CI, 5.4–9.1) in the TPC arm.

“Sac-TMT is the first TROP2 ADC to demonstrate an improvement in overall survival in advanced or recurrent endometrial cancer in this setting compared to chemotherapy in a global Phase 3 trial. In addition, TroFuse-005 found a higher response rate and longer duration of response among patients treated with sac-TMT compared to chemotherapy,” said Dr. Domenica Lorusso, the study’s global lead investigator, lead investigator for ENGOT and professor of Obstetrics and Gynecology at Humanitas University and Humanitas San Pio X, Milan. “The incidence and mortality rates of endometrial cancer are increasing worldwide, and the results from TroFuse-005 have the potential to change the way we treat patients who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy.”

“Sac-TMT demonstrated an improvement in overall survival of almost seven months for women with endometrial cancer who progress following treatment with platinum-based chemotherapy and anti-PD-1 therapy, a meaningful advancement for these women who face a median survival of less than a year with current therapies,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “We believe sac-TMT, with its unique bifunctional linker, can become a cornerstone for the treatment of certain patients with advanced or recurrent endometrial cancer. Based on discussions with the U.S. FDA, the company is hopeful for an approval before the PDUFA date to bring sac-TMT to patients as quickly as possible.”

The safety profile was consistent with what has been observed in previously reported studies of sac-TMT; no new safety signals were observed. Treatment-related adverse events (TRAEs) of any grade occurred in 97.1% of patients treated with sac-TMT and 89.6% of patients receiving TPC. These AEs were mostly low grade and manageable with supportive care and dose modifications, with low discontinuation rates. Grade ≥3 TRAEs occurred in 54.4% and 41.4% of patients, respectively. The most common Grade ≥3 clinical safety events with sac-TMT were anemia (23.7%), neutropenia (20.1%) and oral mucositis/stomatitis (9.9%). Treatment discontinuation rate in the sac-TMT arm was 3.1% and in the TPC arm was 4.9%. Health-related quality of life was maintained over time with sac-TMT. TRAEs led to death in 0.8% of patients (N=3) in each arm.

Based on data from the TroFuse-005 trial, the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) seeking approval of sac-TMT for the treatment of adult patients with endometrial cancer who have previously received platinum containing chemotherapy and a programmed death receptor 1 (PD 1) or programmed death ligand 1 (PD L1) inhibitor, separately or in combination. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of June 15, 2027. Merck will also discuss these data with global regulatory authorities.

Merck’s TroFuse clinical development program for sac-TMT currently consists of 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. Ten of the Phase 3 trials are in women’s cancers, building on Merck’s deep expertise and commitment to women’s cancers research. This includes the ongoing TroFuse-033 trial in first line mismatch repair proficient endometrial cancer. The program is evaluating sac-TMT across a diverse range of tumor types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers, and it spans early-to-late-stage disease as both monotherapy and in combination with immunotherapies. TroFuse-005 is among the 14 of these Phase 3 studies which aim to address unmet medical need with first-in-class opportunities.

About TroFuse-005
TroFuse-005 is a randomized, active-controlled, open-label, multicenter, global Phase 3 trial (ClinicalTrials.gov, NCT06132958) evaluating sac-TMT versus TPC in patients with endometrial carcinoma who have received prior platinum-based chemotherapy and anti-PD-1/anti-PD-L1 immunotherapy either together or separately. The trial enrolled 776 patients who were randomized to receive either sac-TMT or TPC, consisting of doxorubicin or paclitaxel. Sac-TMT (4 mg/kg) was administered on Day 1 of each two-week treatment cycle. Doxorubicin (60 mg/m²) was administered on Day 1 of each three-week treatment cycle and paclitaxel (80 mg/m²) was administered on Days 1, 8 and 15 of each four-week treatment cycle.

The study has dual primary endpoints: PFS by blinded independent central review (BICR), defined as the time from randomization to the first documented disease progression or death from any cause, and OS, defined as the time from randomization to death from any cause. A key secondary endpoint is ORR, and other secondary endpoints include duration of response, incidence of adverse events, treatment discontinuation due to adverse events and change from baseline in global health status/quality-of-life scores.

About sacituzumab tirumotecan (sac-TMT)
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a unique bifunctional linker designed with the potential to maximize payload delivery to tumor cells and minimize payload loss while circulating in the body.

TROP2 is overexpressed on tumor cells compared to healthy cells in many common cancers, and through the TroFuse clinical development program, Merck is evaluating sac-TMT in 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The TroFuse development program spans early-to-late-stage disease in more than nine disease areas and includes more than 15,000 patients worldwide. Numerous Phase 3 trials are exploring sac-TMT as monotherapy and in combination with immunotherapies, aiming to improve survival and quality of life for patients with advanced and earlier-stage cancers.

About endometrial cancer
Endometrial cancer (also referred to as endometrial carcinoma) begins in the inner lining of the uterus, which is known as the endometrium, and is the most common type of cancer in the uterus. More than 90% of uterine body cancers occur in the endometrium. In the U.S., it is estimated there will be approximately 68,270 patients diagnosed with endometrial cancer and approximately 14,450 patient deaths from the disease in 2026. Globally, endometrial cancer is the sixth most common cancer in women and the 15th most common cancer overall. Following primary treatment, patients face a risk of their cancer returning, often as distant metastasis, which is associated with poorer outcomes.

About Merck’s research in women’s cancers
Merck is advancing research aimed at expanding treatment options for certain breast and gynecologic (ovarian, cervical and endometrial) cancers, with a goal of improving outcomes for more patients affected by these diseases. Breast cancer and gynecologic cancers are the first and second most commonly occurring cancer types among women worldwide, respectively, and Merck aims to provide options to patients facing these devastating diseases. With more than 30 clinical trials in more than 20,000 patients around the world, Merck is driving innovative research to purposefully advance standards of care in women’s cancers. Merck’s research efforts include trials focused on evaluating its medicines in earlier stages, as well as identifying novel mechanisms and new combinations with these treatments. Through our portfolio and pipeline, Merck is working to address the impact of women’s cancers on patients, their families and communities globally.

About the Merck and Kelun-Biotech strategic collaboration
Sac-TMT was developed by Kelun-Biotech. Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Under a collaboration agreement, Kelun-Biotech has granted Merck the exclusive rights to develop, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macau and Taiwan).

Merck’s focus on cancer
Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 20 novel mechanisms. With one of the largest clinical development programs across more than 25 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology.

About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Contacts

Media Contacts:

Julie Cunningham

julie.cunningham@merck.com

John Infanti

john.infanti@merck.com

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

Steven Graziano

(732) 594-1583

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors




PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

Two posters highlight preclinical data for PEC 2001 and 3001, a myeloid checkpoint inhibitor and an immunocytokine, supporting advancement toward the clinic

Presentations underscore PharmaEssentia’s strategy to diversify its pipeline through novel immuno-oncology programs targeting both myeloid and PD-1-directed activation of anti-tumor responses

BEDFORD, Mass.–(BUSINESS WIRE)–PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4-8 in Phoenix, Arizona.


The two presentations feature pre-clinical data from PharmaEssentia’s internal R&D portfolio, which builds on the company’s expertise in PEGylated cytokines, novel checkpoint receptor biology, and cytokine engineering technology to extend its focus beyond myeloproliferative neoplasms (MPNs) into solid tumors.

“These presentations reflect the strength of our discovery engine and our ambition to build a pipeline with MPN as its core and broader opportunities beyond,” said Lih-Ling Lin, Ph.D., Chief Scientific Officer at PharmaEssentia. “We look forward to moving our solid tumor pipeline candidates into IND-enabling and Phase 1 studies.”

Poster Presentations

Both posters will be presented during the SITC poster sessions on Friday, November 6.

Title: PEC2001, a differentiated dual LILRB1/LILRB2 antagonist, reprograms myeloid immunity and enhances anti-tumor activity

Poster Number: 411

Presenter: Ali Sepahi, Ph.D., PharmaEssentia

Key Results: PEC2001’s differentiated inhibition mechanism delivered superior selectivity, enhanced anti-tumor immune activation, and strong preclinical efficacy, supporting its potential as a best-in-class myeloid checkpoint inhibitor for solid tumors.

Title: Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile.

Poster Number: 897

Presenter: John Huck, Ph.D., PharmaEssentia

Key Results: PEC3001 selectively enhances anti-tumor T-cell activity through PD-1-directed targeting and IL-2Rα engagement, while minimizing systemic immune activation, supporting advancement into first-in-human clinical development.

About PharmaEssentia

PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia, visit the website or LinkedIn.

PharmaEssentia Innovation Research Center (PIRC), is a subsidiary of PharmaEssentia Corporation. PIRC leads the discovery and preclinical research supporting the early-stage pipeline in the United States. For more information about PIRC, visit their website or LinkedIn.

Contacts

Media Contacts
Muriel Huang

Director, Investor Relations and Corporate Communications

muriel_huang@pharmaessentia.com

Melia Matthews

Manager, Investor Relations and Corporate Communications

melia_matthews@pharmaessentia.com

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling




Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification covers Tempus’ quality management system for “next-generation sequencing devices for cancer genomic profiling to support clinical management.”


xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A published study demonstrated that combining Tempus RNA and DNA testing increases detection of clinically actionable gene fusions compared with DNA testing alone.

IVDR certification supports continued access to xR in the EU beyond 2028, the transition deadline for eligible legacy Class C devices, and provides biopharma partners with an IVDR-certified testing platform to support clinical studies.

“Securing our European IVDR certification for xR reinforces our commitment to meeting the highest regulatory standards globally,” said Lauren Silvis, SVP of External Affairs at Tempus. “This achievement establishes a strong regulatory foundation in Europe as we work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients across the region.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus xR and IVDR certification. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Contacts

Hanah Heintzelman

media@tempus.com

Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026

Carl Zeiss Meditec AG

/ Key word(s): Personnel

Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026

26.10.2026 / 10:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Jena / Oberkochen, October 26, 2026
 
Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026
International medtech executive brings extensive experience in customer-focused innovation and business transformation

Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will take over as CEO of Carl Zeiss Meditec AG on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher had been first announced in May 2026.

With the start date now confirmed, she will assume leadership of Carl Zeiss Meditec Group from Andreas Pecher, who has served as interim CEO since January 1, 2026.

“I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor.

“With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start,“ said Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG.

“We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group,” said Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG.

Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO.

The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).

 

Short profiles:

Bronwyn Brophy O’Connor studied at Dublin City University in Ireland. After earning a bachelor’s degree in International Marketing and Languages (Spanish and French), she completed her Master of Business Administration in 2002. She started her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending her career there as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. Bronwyn then joined Covidien, which was later acquired by Medtronic to form the largest medtech company globally. From 2013 until 2018, she first served as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston, USA. In 2019, Bronwyn joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally, including in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, Bronwyn Brophy O’Connor has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden.

Andreas Pecher studied physics at the University of Würzburg, Germany, and the University of Texas at Austin, USA. He earned a Master of Business Administration (MBA) at the Kellogg School of Management as well as a Master of Engineering Management at the McCormick School of Engineering. He began his career at Motorola (today NXP) in Texas, USA, in 1998. After completing his MBA in 2005, Andreas Pecher worked as a project manager at McKinsey & Company in Germany. Starting in 2010, he headed the Strategy and Business Development department at the solar company Renewable Energy Corporation in Oslo, Norway, and Munich, Germany. In 2013, Andreas Pecher joined the ZEISS Semiconductor Manufacturing Technology (SMT) segment as Head of Strategic Business Development in Oberkochen, Germany. In 2015, he became Head of the Semiconductor Mask Solutions strategic business unit (SMS SBU) and, starting in 2017, headed the Semiconductor Manufacturing Optics strategic business unit. In 2022, Andreas Pecher became Head of the ZEISS SMT segment and was simultaneously appointed a Member of the Executive Board of Carl Zeiss AG. He was named President and CEO of Carl Zeiss AG effective April 1, 2025. In this role, he also took on the interim position as CEO of the publicly listed Carl Zeiss Meditec AG on January 1, 2026, becoming Head of the Medical Technology segment.
 

Contact for investors and the press
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Email: investors.med@zeiss.com
www.zeiss.com/newsroom
 
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med

 


26.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.med@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900GRL4MZ8NMOOK95
EQS News ID: 2422052

 
End of News EQS News Service

2422052  26.10.2026 CET/CEST

Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights

Viromed Medical AG / Key word(s): Capital measures / Capital increase

Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights

26-Oct-2026 / 08:59 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights

Rellingen, October 26, 2026 – With the approval of the Supervisory Board, the Executive Board of Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), resolved today to increase the company’s share capital – excluding shareholders’ subscription rights – from the current EUR 21,250,000 to EUR 21,700,000, an increase of EUR 450,000. This will be achieved by partially utilising Authorised Capital 2025 through the issuance of 450,000 new registered shares with no par value at a placement price of EUR 4.50 each. Initially, the new shares will be subscribed by Small & Mid Cap Investmentbank AG, Munich, and will subsequently be offered to selected investors as part of a private placement.

The gross proceeds from the offering, totalling EUR 2 million, are to be used to finance the company’s working capital.

Notifying person:

Uwe Perbandt, CEO Viromed Medical AG

 

Contact Viromed

E-Mail: kontakt@viromed-medical.de

End of Inside Information


26-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
LEI Code: 894500XR05MYCVCCR171
EQS News ID: 2421728

 
End of Announcement EQS News Service

2421728  26-Oct-2026 CET/CEST